PMID- 36848269
OWN - NLM
STAT- MEDLINE
DCOM- 20230301
LR  - 20240202
IS  - 1945-8932 (Electronic)
IS  - 1945-8924 (Print)
IS  - 1945-8932 (Linking)
VI  - 37
IP  - 2
DP  - 2023 Mar
TI  - B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of 
      Omalizumab Treatment.
PG  - 182-192
LID - 10.1177/19458924221147770 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are two 
      prevalent nasal diseases where both type 2 inflammation and immunoglobulin E 
      (IgE) may play important roles. Although they can exist independently or 
      comorbidly, subtle but important differences exist in immunopathogenesis. 
      OBJECTIVE: To summarize current knowledge of pathophysiological roles of B 
      lineage cells and IgE in AR and CRS with nasal polyps (CRSwNP). METHODS: Searched 
      PubMed database, reviewed AR and CRSwNP-related literature, and discussed disease 
      diagnosis, comorbidity, epidemiology, pathophysiology, and treatment. 
      Similarities and differences in B-cell biology and IgE are compared in the 2 
      conditions. RESULTS: Both AR and CRSwNP have evidence for pathological type 2 
      inflammation, B-cell activation and differentiation, and IgE production. However, 
      distinctions exist in the clinical and serological profiles at diagnosis, as well 
      as treatments utilized. B-cell activation in AR may more frequently be regulated 
      in the germinal center of lymphoid follicles, whereas CRSwNP may occur via 
      extrafollicular pathways although controversies remain in these initial 
      activating events. Oligoclonal and antigen-specific IgE maybe predominate in AR, 
      but polyclonal and antigen-nonspecific IgE may predominate in CRSwNP. Omalizumab 
      has been shown efficacious in treating both AR and CRSwNP in multiple clinical 
      trials but is the only Food and Drug Administration-approved anti-IgE biologic to 
      treat CRSwNP or allergic asthma. Staphylococcus aureus frequently colonizes the 
      nasal airway and has the ability to activate type two responses including B-cell 
      responses although the extent to which it modulates AR and CRSwNP disease 
      severity is being investigated. CONCLUSION: This review highlights current 
      knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP 
      and a small comparison between the 2 diseases. More systemic studies should be 
      done to elevate the understanding of these diseases and their treatment.
FAU - Bai, Junqin
AU  - Bai J
AUID- ORCID: 0000-0001-6012-2809
AD  - Department of Otolaryngology, 12244Northwestern University Feinberg School of 
      Medicine, Chicago, Illinois.
FAU - Tan, Bruce K
AU  - Tan BK
AD  - Department of Otolaryngology, 12244Northwestern University Feinberg School of 
      Medicine, Chicago, Illinois.
AD  - Division of Allergy and Immunology, Department of Medicine, 12244Northwestern 
      University Feinberg School of Medicine, Chicago, Illinois.
LA  - eng
GR  - P01 AI145818/AI/NIAID NIH HHS/United States
GR  - R01 AI134952/AI/NIAID NIH HHS/United States
GR  - R01 DC016645/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - United States
MH  - Humans
MH  - *Immunoglobulin E
MH  - Omalizumab/therapeutic use
MH  - *Rhinitis, Allergic/drug therapy/epidemiology
MH  - B-Lymphocytes
MH  - Inflammation
PMC - PMC10830379
OTO - NOTNLM
OT  - B cell
OT  - allergic rhinitis
OT  - autoantibody
OT  - chronic rhinosinusitis with nasal polyps
OT  - extrafollicular
OT  - germinal center
OT  - immunoglobulin E
OT  - omalizumab
OT  - plasma cell
OT  - type 2 inflammation
COIS- The author(s) declared the following potential conflicts of interest with respect 
      to the research, authorship, and/or publication of this article: B. K. Tan 
      reports personal fees from Sanofi Regeneron/Genzyme.
EDAT- 2023/02/28 06:00
MHDA- 2023/03/03 06:00
PMCR- 2023/03/01
CRDT- 2023/02/27 12:34
PHST- 2023/02/27 12:34 [entrez]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 10.1177_19458924221147770 [pii]
AID - 10.1177/19458924221147770 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2023 Mar;37(2):182-192. doi: 10.1177/19458924221147770.